Treatment of chronic hepatitis C in patients with cirrhosis

Current Opinion in Gastroenterology

Volumn 32, Issue 3, 2016, Pages 143-151

  Chen, Tianyan ^a   Terrault, Norah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Compensated cirrhosis; Decompensated cirrhosis; Direct acting antivirals; Fibrosis regression; Survival; Sustained virological response

Indexed keywords

ASUNAPREVIR; CREATININE; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MORTALITY; REVIEW; VIRAL CLEARANCE; CHRONIC KIDNEY FAILURE; COMPLICATION; GENETICS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84961960771     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000263     Document Type: Review

References (62)

1. WHO. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html-incidence 2015 [Accessed 17 December 2015].
2. Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353-1363.
3. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.
4. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-2895.
5. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10:1003-1019.
6. AASLD/IDSA/IAS-USA. HCV Guidance: recommendations for testing, managing, and treating hepatitis C. Updated Sept 24, 2015. Available from: http://hcvguidelines.org [Accessed 17 December 2015].
7. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51:2069-2076.
8. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56:532-543.
9. Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5:932-937.
10. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Inter Med 2008; 149:399-403.
11. Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61:730-740.
12. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158:329-337.
13. http://www.gilead.com/-/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf. [Accessed 17 December 2015].
14. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010; 49:509-533.
15. Honer Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 2016; 62:561-567.
16. Abbvie Corporation. North Chicago I. Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) [package insert]. 2014.
17. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765.
18. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150:419-429.
19. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis nonresponsive to previous protease-inhibitor therapy: a randomised, doubleblind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397-404.
20. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
21. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-1982.
22. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016; 64:301-307.
23. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
24. Fontana RJ, Poordad F, Schiff ER, et al. Improvement in liver disease parameters following treatment with daclatasvir + sofosbuvir and ribavirin in patients with chronic HCV infection and advanced cirrhosis. Hepatology 2015; 62 (suppl 1):558A.
25. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: ALLY-1 Phase 3 Study EASL-The International Liver Congress 2015, 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria 2015; April 22-26.
26. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1075-1086.
27. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163:1-13.
28. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599-2607.
29. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
30. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
31. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
32. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383:515-523.
33. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-2617.
34. Asselah T, Reesink H, Gerstoft J, et al. High efficacy of elbasvir and grazoprevir with 446 or without ribavirin in 103 treatment-nave and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology 2015; 62 (1 suppl):340A.
35. Saxena V, Koraishy FM, Sise M, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-target. EASL 2015. LP-08. J Hepatol 2015; 62:S267.
36. Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based directacting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015; 47:924-929.
37. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1 patients with end-stage renal disease on hemodialysis or GFR <30mL/min. Liver Int 2015. doi: 10.1111/liv.13025.
38. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir + dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. EASL 2015. LO-1. Hepatology 2015; 62 (suppl):716-717.
39. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386:1537-1545.
40. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 48:108-116.
41. Poordad F, Schiff E, Vierling J, et al. Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Posttransplant Recurrence: ALLY-1 Phase 3 Study. 2015.
42. http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm. 2015. [Accessed 17 December 2015].
43. Mantry P, Hanson J, Trinh R, et al. Ombitasvir/paritaprevir/r and dasabuvir with ribavirin for HCV genotype 1 patients with decompensated cirrhosis. Hepatology 2015; 62 (suppl):A558.
44. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150:419-429.
45. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62:715-725.
46. Aqel B, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62:1004-1012.
47. Lawitz E, Poordad F, Gutierrez J, et al. SVR12 results from the phase II, openlabel IMPACT study of simeprevir, in combination with daclatasvir and sofosbuvir in treatment-naive and experienced patients with chronic HCV genotype 1/4 infection and decompensated disease. Hepatology. 2015; 62 (suppl)(October):227A.
48. Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62:79-86.
49. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2015. [Epub ahead of print]
50. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol 2016. [Epub ahead of print]
51. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62:715-725.
52. Manns M, Forns X, Samuel D, et al. Ledipasvir-sofosbuvir with ribavirin is safe and efficacious in decompensated and postliver transplantation patients with HCV infection: Preliminary results of the SOLAR-2 trial. J Hepatol. 2015(Suppl 2):Abstract.
53. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618-2628.
54. Modi AA, Nazario H, Trotter JF, et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl 2016; 22:281-286.
55. Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016. [Epub ahead of print]
56. Hezode C, de Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015; 62 (1 suppl):314A.
57. Welzel T, Petersen J, Ferenci P, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program. Hepatology 2015; 62 (1 suppl):225A.
58. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015; 15:1049-1054.
59. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149:649-659.
60. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatmentexperienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385:2502-2509.
61. Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015; 63:581-585.
62. Hassanein T, Sims KD, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015; 62:1204-1206.